Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

NCT07741643 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

HNSCC,Larynx, Pharynx and Oral Cavity
Squamous Cell Carcinoma
Head and Neck Cancer
Head and Neck Surgery

Interventions

DRUG: Panitumumab-IRDye800
DRUG: [18F]NOTA-ABY-030

Sponsor

Vanderbilt-Ingram Cancer Center